ABCC2 (MRP2, cMOAT) localized in the nuclear envelope of breast carcinoma cells correlates with poor clinical outcome

Pathology and Oncology Research

Volumn 18, Issue 2, 2012, Pages 331-342

  MacIejczyk, Adam ^a   Jagoda, Ewa ^b   Wysocka, Teresa ^b   Matkowski, Rafał ^b   Györffy, Balázs ^c   Lage, Hermann ^d   Surowiak, Paweł ^a,b,d  

^a Wroclaw   (Poland)

^b WROCLAW MEDICAL UNIVERSITY   (Poland)

^c INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

ABCC2; Breast cancer; Immunohistochemistry; Prognosis

Indexed keywords

ANTINEOPLASTIC AGENT; ESTROGEN RECEPTOR; HORMONE; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 2; PROGESTERONE RECEPTOR; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST CARCINOMA; CANCER CELL; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CELL MEMBRANE; CELL NUCLEUS MEMBRANE; CONTROLLED STUDY; CYTOPLASM; DISEASE FREE SURVIVAL; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MASTECTOMY; NUCLEAR LOCALIZATION SIGNAL; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PARTIAL MASTECTOMY; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SEGMENTAL MASTECTOMY; SURVIVAL TIME;

BREAST NEOPLASMS; CYTOPLASM; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; MIDDLE AGED; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEOPLASM STAGING; NUCLEAR ENVELOPE; PROGNOSIS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84863477006     PISSN: 12194956     EISSN: 15322807     Source Type: Journal    
DOI: 10.1007/s12253-011-9449-9     Document Type: Article

References (29)

1. Steward BW, Kleihues P (2003) World cancer report. IARC Press, Lyon
2. Tabar L, Yen MF, Vitak B et al (2003) Mammography service screening and mortality in breast cancer patients: 20-year followup before and after introduction of screening. Lancet 361:1405-1410
3. Gottesman MM, Fojo T, Bates SE (2002) Multidrug resistance in cancer: role of ATP-dependent transporters. Nature 2:48-58
4. Lage H (2003) ABC-transporters: implications on drug resistance from microorganisms to human cancers. Int J Antimicrob Agents 22:188-199
5. Wada M, Toh S, Taniguchi K et al (1998) Mutations in the canalicular multispecific organic anion transporter (cMOAT) gene, a novel ABC transporter, in patients with hyperbilirubinemia II/Dubin-Johnson syndrome. Hum Mol Genet 7:203-207
6. Taniguchi K, Wada M, Kohno K et al (1996) A human canalicular multispecific organic anion transporter (cMOAT) gene is overexpressed in cisplatin-resistant human cancer cell lines with decreased drug accumulation. Cancer Res 56:4124-4129
7. Materna V, Stege A, Surowiak P et al (2006) RNA interferencetriggered reversal of ABCC2-dependent cisplatin resistance in human cancer cells. Biochem Biophys Res Com 348:153-157
8. Kowalski P, Surowiak P, Lage H (2005) Reversal of drug-resistant phenotypes by an autocatalytic multitarget multiribozyme directed against the transcripts of the ABC transporters MDR1/P-gp, MRP2, and BCRP. Mol Ther 11:508-522
9. Surowiak P, Materna V, Kaplenko I et al (2006) ABCC2 (MRP2, cMOAT) can be localized in the nuclear membrane of ovarian carcinomas and correlates with resistance to cisplatin and clinical outcome. Clin Cancer Res 12(23):7149-7158
10. Surowiak P, Materna V, Maciejczyk A et al (2007) Nuclear metallothionein expression correlates with cisplatin resistance of ovarian cancer cells and poor clinical outcome. Virchows Arch 450(3):279-285
11. Materna V, Surowiak P, Kaplenko I et al (2007) Taxol-resistanceassociated gene-3 (TRAG-3/CSAG2) expression is predictive for clinical outcome in ovarian carcinoma patients. Virchows Arch 450(2):187-194
12. Sobin LH, Wittekind C (2002) TNM classification of malignant tumors. AJCC, Wiley-Liss, New York
13. Remmele W, Stegner HE (1987) Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue (Article in German). Pathologe 8:138-140
14. Surowiak P, Materna V, Matkowski R et al (2005) Relationship between cyclooxygenase 2 and MDR1/P-glycoprotein expressions in invasive breast cancers and their prognostic significance. Breast Cancer Res 7:862-870
15. http://cubic.bioc.columbia.edu/cgi/var/nair/resonline.pl
16. Gyorffy B, Lanczky A, Eklund AC et al (2010) An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1809 patients. Breast Cancer Res Treat 123(3):725-731
17. Statistica PL (2007) (Statsoft, Poland).
18. Szczuraszek K, Materna V, Halon A et al (2009) Positive correlation between cyclooxygenase-2 and ABC-transporter expression in non-Hodgkin's lymphomas. Oncol Rep 22(6):1315-1323
19. Dean M, Fojo T, Bates S (2005) Tumour stem cells and drug resistance. Nat Rev Cancer 5:275-284
20. Donnenberg VS, Donnenberg AD (2005) Multiple drug resistance in cancer revisited: the cancer stem cell hypothesis. J Clin Pharmacol 45:872-877
21. Kiyotani K, Mushiroda T, Imamura CK et al (2010) Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients. J Clin Oncol 28(8):1287-1293
22. Qiu R, Kalhorn TF, Slattery JT (2004) ABCC2-mediated biliary transport of 4-glutathionylcyclophosphamide and its contribution to elimination of 4-hydroxycyclophosphamide in rat. J Pharmacol Exp Ther 308(3):1204-1212
23. Rau T, Erney B, Göres R et al (2006) High-dose methotrexate in pediatric acute lymphoblastic leukemia: impact of ABCC2 polymorphisms on plasma concentrations. Clin Pharmacol Ther 80 (5):468-476
24. Vlaming ML, van Esch A, Pala Z et al (2009) Abcc2 (Mrp2), Abcc3 (Mrp3), and Abcg2 (Bcrp1) are the main determinants for rapid elimination of methotrexate and its toxic metabolite 7-hydroxymethotrexate in vivo. Mol Cancer Ther 8(12):3350-3359
25. Hulot JS, Villard E, Maguy A et al (2005) A mutation in the drug transporter gene ABCC2 associated with impaired methotrexate elimination. Pharmacogenet Genomics 15(5):277-285
26. Hinoshita E, Uchiumi T, Taguchi K et al (2000) Increased expression of an ATP-binding cassette superfamily transporter, multidrug resistance protein 2, in human colorectal carcinomas. Clin Cancer Res 6(6):2401-2407
27. Fujita K, Nagashima F, Yamamoto W et al (2008) Association of ATP-binding cassette, sub-family C, number 2 (ABCC2) genotype with pharmacokinetics of irinotecan in Japanese patients with metastatic colorectal cancer treated with irinotecan plus infusional 5-fluorouracil/leucovorin (FOLFIRI). Biol Pharm Bull 31(11):2137-2142
28. O'Brian CA, Kreso A, Dick JE (2009) Cancer stem cells in solid tumors: an overview. Semin Radiat Oncol 19(2):71-77
29. Materna V, Stege A, Surowiak P et al (2006) RNA interferencetriggered reversal of ABCC2-dependent cisplatin resistance in human cancer cells. Biochem Biophys Res Com 348(1):153-157